|
 |
| |
| |
|
|
The laboratory of Mark I. Greene, M.D., Ph.D., F.R.C.P., focuses on the origin, detection, and therapy of breast cancer. His work has deepened our understanding of how the cancer-causing gene called neu oncogene causes breast cells to become malignant. Greene and colleagues identified the neu oncogene, determined its role in malignancy, and defined the principles that led to the development of the first approved therapy that targets the proteins of this gene. Greene also was the first to develop the basic principles by which homodimerization and heterodimers formed in the erbB system and is trying to extend those principles to optimize therapeutic approaches.
By understanding the atomic changes in neu that contribute to malignancy, Greene and his team hope to find better ways to disable those changes. Greene and his colleagues use crystallography and structural approaches to design new drug therapies for erbB related tumors and TNF superfamily related signaling. Greene and his laboratory have developed small molecule therapy for tumors caused by members of the erbB family that they expect will be administered orally and should have very limited if any toxicity. A major new area of interest is the assembly and structure of the centrosome and the development of drugs which limit aneuploidy.
Background
Mark Greene received his M.D. in 1972 from the University of Manitoba in Canada and his Ph.D. in Immunochemistry from the same institution in 1977. Mark Greene also received the FRCP from the Royal College in 1976. In 1976 Dr. Greene moved from Canada to Harvard University where he was a Medical Research Council Fellow. Greene was appointed Assistant Professor of Pathology at Harvard Medical School and University in 1978. In 1980 he rose to Associate Professor in the Harvard Department of Pathology and at the University and remained there until the end of 1985. Dr. Greene also served as a clinical consultant in Medicine at the Dana Farber Cancer Center from 1980-1986. Greene was recruited to Penn to head the basic research Unit of Immunology in 1986. Since 1987 he has also headed fundamental research at the Cancer Center at Penn and in 1993 became Vice Chair of the Department of Pathology. Dr. Greene was appointed the Newton Abraham Professor of Biological Science at Oxford University. |
|
|
|
| |
| TOP |
|
|
| The University of Pennsylvania Health System © 2007, The Trustees of the University of Pennsylvania. Unauthorized reproduction of this material is strictly prohibited.
|
| Disclaimer | Contact Webmaster |
|
|
|
|
